Keywords: Pfizer, Mylan, Generic Chantix, Allergan, Botox, Marketing practices

Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices

Article | 02 September 2010

Print This

US pharma behemoth Pfizer (NYSE: PFE) has launched a pre-emptive strike against generic drug manufacturer Mylan (Nasdaq; MYL) to protect ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in